Company / EPS (Diluted)
GT Biopharma, Inc. EPS (Diluted) History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.01
FY2020
5-year range
-$13.67 / $119.91
FY2016-FY2020
Trend
-100.0%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-13.67 to $-0.01 over the past 4 years.
Based on SEC 10-K filings.
-0.01 in FY2020.
Improved from $-13.67 to $-0.01 over the past 4 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, eps (diluted) decreased 100.0% year-over-year.
- Peak eps (diluted) was recorded in FY2017.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2020 | -$0.01 | -100.0% |
| FY2017 | $119.91 | +977.2% |
| FY2016 | -$13.67 | -34075.0% |
| FY2015 | -$0.04 | -300.0% |
| FY2014 | -$0.01 | +0.0% |
| FY2013 | -$0.01 | +50.0% |
| FY2012 | -$0.02 | +33.3% |
| FY2011 | -$0.03 | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026